Home >> Tag Archives: Cynvenio Biosystems—

Tag Archives: Cynvenio Biosystems—

Liquid biopsy monitoring program for breast cancer, 7/17

July 2017—Cynvenio Biosystems announced the availability of ClearID Total Insight Breast Cancer, a liquid biopsy monitoring service for patients in treatment and survivors in remission. This comprehensive assessment of a patient’s biological health is designed to measure immune health status and detect genetic mutations associated with cancer.

Cell-free DNA purification upgrade, 3/16

Marketplace Archives

March 2016—Cynvenio Biosystems announced the availability of the Concordia cell-free DNA purification sample preparation upgrade for its multi-template analysis LiquidBiopsy platform.

Cynvenio offers cfDNA purification upgrade

Trial starts for breast cancer liquid biopsy test

Cynvenio announces new PD-L1 test

IGHV clinical utility in CLL and preferred testing practices

Thursday, February 28, 2019, 1PM–2PM ET
Webinar presenter Curtis A. Hanson, MD, Professor of Laboratory Medicine and Pathology Mayo Clinic College of Medicine, Rochester, Minnesota, will review the role of key High Risk (HR) biomarkers in CLL, focusing on clinical evidence and raising awareness for IGHV mutation status as an important CLL biomarker that can help guide treatment decisions. Webinar will also provide best practices for how and when to request IGHV testing and how to perform testing for IGHV mutation status in CLL patients.
Register Now ...

Why DMTs are a critical ingredient in the delivery of value-based care

Tuesday, March 5, 2019, 1PM–2PM ET
Webinar presenters Michael Laposata, MD, PhD, University of Texas Medical Branch at Galveston Pathology, Chairman, and Bruce Friedman, MD, University of Michigan, Pathology, Emeritus Professor, Informatics, will discuss the barriers that exist for the rapid and significant growth of diagnostic management teams to reduce medical error and optimize laboratory test use, overcoming barriers to DMT implementation, addressing connectivity between experts and doctors, and identifying ways to overcome DMT resistance from your peers. This webinar will also be hosted before a live audience at DMT Conference Galveston Island Convention Center, Galveston, Texas.
Register Now ...

MALDI-TOF for the clinical identification of mycobacteria

Webinar presenter Omai Garner, PhD, D(ABMM), Assistant Clinical Professor, Section Chief, Clinical Microbiology, Director, Point of Care Testing, UCLA Department of Pathology and Laboratory Medicine, discusses the implementation and clinical use of MALDI-TOF MS for mycobacterial identification. It covers in detail the clinical data surrounding organism identification. It also explores the lab protocol (workflow impact) and turnaround time improvements (clinical impact) for this new technology. This on-demand webinar originally broadcast on December 13, 2018.
Watch Now

Current and emerging biomarkers: science, technologies, and practicalities

Webinar presenter Sam Caughron, MD, President & Managing Partner, Director of Molecular Lab, MAWD Pathology Group, discusses discusses Pathologists play a crucial role in furthering advancements that may help predict which patients are likely to benefit from immuno-oncology therapies. This webinar will empower you to understand the biology behind current and emerging immuno-oncology biomarkers. This on-demand webinar originally broadcast on November 29, 2018. Watch Now

Resectability in stage III NSCLC:
Case-based considerations for clinical decision making

Webinar presenters Michael Walker, MD, System Chief, Thoracic Surgery, Medical Director, Cancer Program, Main Line Health, and Tracey Evans, MD, Director, Thoracic Oncology Research, Co-Director, Thoracic Oncology Program, Associate Program Director, Hematology/Medical Oncology Fellowship Program, Lankenau Cancer Center, discuss AJCC staging guidelines for lung cancer, specifically Stage III disease. This on-demand webinar originally broadcast on November 14, 2018.
Watch Now

Homologous recombination deficiency and BRCA testing in ovarian and breast cancer

Webinar presenters Dana Chase, MD, Michelle Shiller, DO, and Tabetha Sundin, PhD discuss the role of BRCA1/2 mutations in homologous recombination deficiency and carcinogenesis, homologous recombination deficiency as a marker of treatment sensitivity, the testing process for homologous recombination deficiency and BRCA mutations, and the role of BRCA testing in ovarian and breast cancer. This on-demand webinar originally broadcast on October 23, 2018.
Watch Now

Current and emerging biomarkers: science, technologies, and practicalities

Webinar presenter Tabetha Sundin, PhD, HCLD, MB, discusses the crucial role pathologists play in furthering advancements that may help predict which patients are likely to benefit from immuno-oncology therapies. This webinar will empower you to understand the biology behind current and emerging immuno-oncology biomarkers. This on-demand webinar originally broadcast on October 3, 2018.
Watch Now

Actionable insights from tumor tissue to meet demands of precision medicine: Experience from a NGS System

Webinar presenter Achim Battmann, PD, Chief Physician of the Institute of Pathology, Hospital Northwest in Frankfurt am Main, discusses genetic mutations and their role in precision medicine, the role of cancer genetics in precision medicine, and the evolution of precision medicine. This on-demand webinar originally broadcast on September 26, 2018.
Watch Now

Procalcitonin: once is not enough.
The critical role of serial testing.

Webinar presenters Matthew Bell, Mike Broyles, PharmD, and Eric Gluck, MD, discuss current laboratory/clinical practice, how to use procalcitonin in sepsis and LRTI to determine when to start and stop antibiotic therapy, the importance of procalcitonin assay precision and sensitivity to support clinical decisions, and the impact of procalcitonin testing on antibiotic stewardship. This on-demand webinar originally broadcast on August 21, 2018.
Watch Now